{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T08:59:05Z","timestamp":1774601945872,"version":"3.50.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"AstraZeneca do Brasil Ltda"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Targeted and immunotherapies are currently moving toward early-stage settings for patients with non-small cell lung cancer (NSCLC). Predictive biomarkers data are scarce in this scenario. We aimed to describe the frequency of EGFR mutations and PD-L1 expression levels in early-stage non-squamous patients with NSCLC from a large, single Brazilian oncology center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We retrospectively evaluated patients with NSCLC diagnosed at an early-stage (IB to IIIA-AJCC seventh edition) at Barretos Cancer Hospital (n = 302). EGFR mutational status was assessed in FFPE tumor tissues using distinct methodologies (NGS, Cobas, or Sanger sequencing). PD-L1 expression was evaluated by immunohistochemistry (clone 22C3) and reported as Tumor Proportion Score (TPS), categorized as &amp;lt;1%, 1-49%, and \u226550%. We evaluated the association between EGFR mutational status and PD-L1 expression with sociodemographic and clinicopathological parameters by Fisher\u2019s test, qui-square test, and logistic regression. Survival analysis was assessed by the Kaplan-Meier method and Cox regression model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>EGFR mutations were detected in 17.3% (n = 48) of cases and were associated with female sex, never smokers, and longer overall and event-free survival. PD-L1 positivity was observed in 36.7% (n = 69) of cases [TPS 1-49% n = 44(23.4%); TPS \u226550% n = 25(13.3%)]. PD-L1 positivity was associated with smoking, weight loss, and higher disease stages (IIB\/IIIA).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The frequencies of EGFR mutations and PD-L1 positivity were described for early-stage non-squamous patients with NSCLC. These results will be essential for guiding treatment strategies with the recent approvals of osimertinib and immunotherapy in the adjuvant setting.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyac167","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T18:37:37Z","timestamp":1663094257000},"page":"e899-e907","source":"Crossref","is-referenced-by-count":11,"title":["<i>EGFR<\/i> Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil"],"prefix":"10.1093","volume":"27","author":[{"given":"Icaro","family":"Alves Pinto","sequence":"first","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Rodrigo","family":"de Oliveira Cavagna","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Aline Larissa","family":"Virginio da Silva","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Josiane Mour\u00e3o","family":"Dias","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Iara Vidigal","family":"Santana","sequence":"additional","affiliation":[{"name":"Department of Pathology, Barretos Cancer Hospital , Barretos , Brazil"},{"name":"Molecular Diagnostic Laboratory, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"La\u00edsa Caroline","family":"Souza","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Fl\u00e1vio Augusto","family":"Ferreira da Silva","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Maria Fernanda","family":"Biazotto Fernandes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Gustavo Dix","family":"Junqueira Pinto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Izabella Santos","family":"Negreiros","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Maria Fernanda","family":"Santiago Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Fl\u00e1via Escremim","family":"de Paula","sequence":"additional","affiliation":[{"name":"Molecular Diagnostic Laboratory, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Gustavo N\u00f3riz","family":"Berardinelli","sequence":"additional","affiliation":[{"name":"Molecular Diagnostic Laboratory, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Giovanna Maria Stanfoca","family":"Casagrande","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Marcela","family":"Oliveira da Silva","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Eduardo Caetano","family":"Albino da Silva","sequence":"additional","affiliation":[{"name":"Department of Pathology, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Marco Antonio","family":"de Oliveira","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Alexandre Arthur","family":"Jacinto","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Barretos Cancer Hospital , Barretos , Brazil"}]},{"given":"Vinicius","family":"Duval da Silva","sequence":"additional","affiliation":[{"name":"Department of Pathology, Barretos Cancer Hospital , Barretos , Brazil"},{"name":"Barretos School of Medicine Dr. Paulo Prata, FACISB , Barretos , Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9639-7940","authenticated-orcid":false,"given":"Rui Manuel","family":"Reis","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"},{"name":"Molecular Diagnostic Laboratory, Barretos Cancer Hospital , Barretos , Brazil"},{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho , Braga , Portugal"},{"name":"ICVS\/3B\u2019s, PT Government Associate Laboratory , Braga\/Guimar\u00e3es , Portugal"}]},{"given":"Pedro","family":"De Marchi","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"},{"name":"Oncoclinicas Group , Rio de Janeiro , Brazil"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2200-3985","authenticated-orcid":false,"given":"Let\u00edcia Ferro","family":"Leal","sequence":"additional","affiliation":[{"name":"Molecular Oncology Research Center, Barretos Cancer Hospital , Barretos , Brazil"},{"name":"Barretos School of Medicine Dr. Paulo Prata, FACISB , Barretos , Brazil"}]}],"member":"286","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"issue":"3","key":"2022110514282232100_CIT0001","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"25","key":"2022110514282232100_CIT0002","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1056\/NEJMoa043623","article-title":"Vinorelbine plus cisplatin vs. observation in resected non\u2013small-cell lung cancer","volume":"352","author":"Winton","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"2022110514282232100_CIT0003","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1911793","article-title":"Reduced lung-cancer mortality with volume CT screening in a randomized trial","volume":"382","author":"de Koning","year":"2020","journal-title":"N Engl J Med"},{"issue":"10","key":"2022110514282232100_CIT0004","doi-asserted-by":"crossref","first-page":"S1009","DOI":"10.1016\/j.jtho.2019.08.2227","article-title":"EP1.11-06 design and implementation of an integrated lung cancer prevention and screening program using a mobile CT in Brazil","volume":"14","author":"Chiarantano","year":"2019","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2022110514282232100_CIT0005","first-page":"242","article-title":"Recurrence after surgery in patients with NSCLC","volume":"3","author":"Uramoto","year":"2014","journal-title":"Transl. Lung Cancer Res"},{"issue":"3","key":"2022110514282232100_CIT0006","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/S1010-7940(97)00198-X","article-title":"Disease recurrence after resection for stage I lung cancer.","volume":"12","author":"Al-Kattan","year":"1997","journal-title":"Eur J Cardio-thoracic Surg"},{"issue":"8","key":"2022110514282232100_CIT0007","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1055\/s-0029-1185734","article-title":"Early recurrence after surgical resection in patients with pathological stage i non-small cell lung cancer","volume":"57","author":"Kawachi","year":"2009","journal-title":"Thorac Cardiovasc Surg"},{"issue":"21","key":"2022110514282232100_CIT0008","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1200\/JCO.2007.13.9030","article-title":"Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE collaborative group","volume":"26","author":"Pignon","year":"2008","journal-title":"J Clin Oncol"},{"issue":"2","key":"2022110514282232100_CIT0009","first-page":"191","article-title":"Adjuvant chemotherapy in non-small cell lung cancer: State-of the-art","volume":"4","author":"Cort\u00e9s","year":"2015","journal-title":"Transl. Lung Cancer Res"},{"issue":"7","key":"2022110514282232100_CIT0010","doi-asserted-by":"crossref","first-page":"807","DOI":"10.6004\/jnccn.2018.0062","article-title":"NCCN guidelines insights: non\u2013small cell lung cancer, version 5.2018.","volume":"16","author":"Ettinger","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"2022110514282232100_CIT0011","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1038\/s41598-019-39965-x","article-title":"Mutational profile of Brazilian lung adenocarcinoma unveils association of EGFR mutations with high Asian ancestry and independent prognostic role of KRAS mutations","volume":"9","author":"Leal","year":"2019","journal-title":"Sci Rep"},{"issue":"5","key":"2022110514282232100_CIT0012","first-page":"1","article-title":"Analysis of predictive biomarkers in patients with lung adenocarcinoma from southern Brazil reveals a distinct profile from other regions of the country","volume":"1","author":"Andreis","year":"2019","journal-title":"J Glob Oncol"},{"issue":"4","key":"2022110514282232100_CIT0013","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1634\/theoncologist.2018-0254","article-title":"EGFR mutation testing: changing patterns of molecular testing in Brazil","volume":"24","author":"Palacio","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"2022110514282232100_CIT0014","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/s41588-019-0569-6","article-title":"Genomic landscape of lung adenocarcinoma in East Asians","volume":"52","author":"Chen","year":"2020","journal-title":"Nat Genet"},{"issue":"1","key":"2022110514282232100_CIT0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/JTO.0b013e3181fb4fe2","article-title":"Frequency of EGFR and KRAS mutations in lung adenocarcinomas in african americans","volume":"6","author":"Reinersman","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2022110514282232100_CIT0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.01734-2016","article-title":"Molecular biomarkers for lung adenocarcinoma","volume":"49","author":"Calvayrac","year":"2017","journal-title":"Eur Respir J"},{"issue":"9","key":"2022110514282232100_CIT0017","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41568-019-0179-8","article-title":"Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy","volume":"19","author":"Skoulidis","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"2022110514282232100_CIT0018","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"issue":"21","key":"2022110514282232100_CIT0019","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non\u2013small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"2022110514282232100_CIT0020","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"2022110514282232100_CIT0021","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1200\/JCO.2018.36.15_suppl.9014","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor (TKI) na\u00efve patients with advanced NSCLC","volume":"36","author":"Lisberg","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022110514282232100_CIT0022","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10308","key":"2022110514282232100_CIT0023","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/S0140-6736(21)02098-5","article-title":"Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB\u2013IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial","volume":"398","author":"Felip","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2022110514282232100_CIT0024","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000376552","article-title":"Mutational profile and New IASLC\/ATS\/ERS classification provide additional prognostic information about lung adenocarcinoma: a study of 125 patients from Brazil","volume":"89","author":"de Melo","year":"2015","journal-title":"Oncology"},{"issue":"5","key":"2022110514282232100_CIT0025","doi-asserted-by":"crossref","first-page":"419","DOI":"10.6061\/clinics\/2012(05)03","article-title":"Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients","volume":"67","author":"Bacchi","year":"2012","journal-title":"Clinics"},{"issue":"3","key":"2022110514282232100_CIT0026","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1158\/2159-8290.CD-20-1165","article-title":"Genetic ancestry contributes to somatic mutations in lung cancers from admixed latin american populations","volume":"11","author":"Carrot-Zhang","year":"2021","journal-title":"Cancer Discov"},{"issue":"2","key":"2022110514282232100_CIT0027","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1158\/1940-6207.CAPR-20-0179","article-title":"The performance of colorectal cancer screening in Brazil: the first two years of the implementation program in barretos cancer hospital.","volume":"14","author":"Guimar\u00e3es","year":"2021","journal-title":"Cancer Prev Res"},{"issue":"2","key":"2022110514282232100_CIT0028","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1590\/1678-4685-gmb-2014-0364","article-title":"Oncogenetics service and the Brazilian public health system: the experience of a reference cancer hospital","volume":"39","author":"Palmero","year":"2016","journal-title":"Genet Mol Biol"},{"issue":"2","key":"2022110514282232100_CIT0029","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"3","key":"2022110514282232100_CIT0030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000507373","article-title":"Mutational profiling of driver tumor suppressor and oncogenic genes in Brazilian malignant pleural mesotheliomas","volume":"87","author":"Campanella","year":"2020","journal-title":"Pathobiology"},{"issue":"D1","key":"2022110514282232100_CIT0031","doi-asserted-by":"crossref","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","article-title":"ClinVar: improving access to variant interpretations and supporting evidence","volume":"46","author":"Landrum","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"2022110514282232100_CIT0032","first-page":"109-1","article-title":"A PCR-based approach for driver mutation analysis of EGFR, KRAS, and BRAF genes in lung cancer tissue sections.","volume-title":"Methods in Molecular Biology","author":"de Oliveira Cavagna","year":"2021"},{"issue":"11","key":"2022110514282232100_CIT0033","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1136\/jclinpath-2020-206832","article-title":"PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC)","volume":"74","author":"De Marchi","year":"2021","journal-title":"J Clin Pathol"},{"issue":"7","key":"2022110514282232100_CIT0034","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/1759-7714.12651","article-title":"EGFR mutations in early-stage and advanced-stage lung adenocarcinoma: analysis based on large-scale data from China","volume":"9","author":"Pi","year":"2018","journal-title":"Thorac Cancer"},{"issue":"36","key":"2022110514282232100_CIT0035","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"2022110514282232100_CIT0036","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/JTO.0b013e31827914ea","article-title":"Lungs don\u2019t forget: comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers","volume":"8","author":"Varghese","year":"2013","journal-title":"J Thorac Oncol"},{"issue":"22","key":"2022110514282232100_CIT0037","doi-asserted-by":"crossref","first-page":"6169","DOI":"10.1158\/1078-0432.CCR-11-3265","article-title":"Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: Higher susceptibility of women to smoking-related KRAS-mutant cancers","volume":"18","author":"Dogan","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2022110514282232100_CIT0038","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2022110514282232100_CIT0039","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"2022110514282232100_CIT0040","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"2022110514282232100_CIT0041","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum\u2013pemetrexed in EGFR T790M\u2013positive lung cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N Engl J Med"},{"issue":"18","key":"2022110514282232100_CIT0042","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"2022110514282232100_CIT0043","doi-asserted-by":"crossref","first-page":"LBA5","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA5","article-title":"Osimertinib as adjuvant therapy in patients (pts) with stage IB\u2013IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"issue":"18","key":"2022110514282232100_CIT0044","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1056\/NEJMe2029532","article-title":"Adjuvant osimertinib in EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Planchard","year":"2020","journal-title":"N Engl J Med"},{"key":"2022110514282232100_CIT0045"},{"issue":"2","key":"2022110514282232100_CIT0046","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.lungcan.2015.05.007","article-title":"PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma","volume":"89","author":"Cooper","year":"2015","journal-title":"Lung Cancer"},{"issue":"9","key":"2022110514282232100_CIT0047","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","article-title":"Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody","volume":"3","author":"Stewart","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"24","key":"2022110514282232100_CIT0048","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"2022110514282232100_CIT0049","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2022110514282232100_CIT0050","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-20-1680","article-title":"The next decade of immune checkpoint therapy","volume":"11","author":"Sharma","year":"2021","journal-title":"Cancer Discov"},{"issue":"4","key":"2022110514282232100_CIT0051","doi-asserted-by":"crossref","first-page":"804","DOI":"10.3390\/cancers13040804","article-title":"Targeted therapy in advanced and metastatic non-small cell lung cancer. An update on treatment of the most important actionable oncogenic driver alterations","volume":"13","author":"K\u00f6nig","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/11\/e899\/46832217\/oyac167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/11\/e899\/46832217\/oyac167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T14:30:31Z","timestamp":1667658631000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/11\/e899\/6696863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":51,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,9,13]]},"published-print":{"date-parts":[[2022,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac167","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,11,1]]},"published":{"date-parts":[[2022,9,13]]}}}